In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...
Read MoreCurrent disease status-First occurrence of the lymphoma Posts on Medivizor
Fertility options for female patients with lymphoma or leukemia
In a nutshell This article reviewed different options to preserve or restore fertility in female patients with lymphoma or leukemia. Some background Impaired reproductive function is one possible side effect of aggressive chemotherapy and radiotherapy for cancer. In severe cases, intensive anti-cancer treatment can lead to fertility loss. 7 to 9% of...
Read MoreCan immune profiling help predict outcomes for patients with NHL after a stem cell transplant?
In a nutshell This study compared the outcomes of filgrastim (Neupogen) treatment with versus without plerixafor (Mozobil) in patients with B-cell non-Hodgkin's lymphoma (NHL) after a stem cell transplant. The authors concluded that certain immune cell biomarkers were associated with poorer long-term survival for these patients. Some...
Read MoreEvaluating different doxorubicin doses for patients with diffuse large B-cell lymphoma
In a nutshell This study evaluated three different chemotherapy regimens with varying doses of doxorubicin (Adriamycin) for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that R-CEOP70 could be safely used instead of R-CHOP50, while R-CEOP90 may be recommended for younger patients. Some background DLBCL is one of the most...
Read MoreEvaluating outcomes for patients with follicular lymphoma after rituximab maintenance therapy
In a nutshell This study looked at long-term outcomes for patients with follicular lymphoma after rituximab (Rituxan) maintenance therapy. This study concluded that rituximab maintenance helped improve long-term survival without disease progression compared to no treatment. Some background Follicular lymphoma (FL) is the second most common type of...
Read MoreLooking for patients with previously untreated mantle cell lymphoma to test a treatment combination
In a nutshell This phase 3 study is evaluating the effectiveness and safety of two different chemotherapy regimens for patients with mantle cell lymphoma (MCL). The main outcome to be measured will be the number of patients who survive without tumor growth or spread. This study is recruiting in Las Vegas, Nevada in the U.S. The details MCL is an...
Read MoreFirst-line treatment options for patients with Hodgkin’s lymphoma
In a nutshell This article reviewed different options for first-line treatment for Hodgkin lymphoma (HL). Some background Treatment for patients with HL has become more individualized. Treatment strategies have been adapted to disease risk, and how well patients respond to initial treatment. The goal of these approaches is to reduce side effects...
Read MoreSearching for patients with untreated small lymphocytic lymphoma to test combined immunotherapy
In a nutshell This phase 2 study is evaluating the effectiveness of a new combination therapy for small lymphocytic lymphoma (SLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is recruiting in Rochester, New York, US. The details Typical treatments for SLL include...
Read MoreReviewing the risk of neutropenia after first-line treatment for advanced Hodgkin lymphoma
In a nutshell This article reviewed the risk of patients with advanced Hodgkin lymphoma (HL) developing neutropenia after first-line treatment. This study concluded that this condition can be a serious complication for these patients. Some background The most commonly used frontline chemotherapy regimens for advanced HL are ABVD (doxorubicin,...
Read MoreEvaluating RBD chemotherapy for recurrent or non-responsive non-Hodgkin lymphoma
In a nutshell This study evaluated how safe and effective RBD (rituximab, bendamustine, and dexamethasone) chemotherapy was for patients with B-cell non-Hodgkin lymphoma (NHL). This study concluded that this new regimen showed promising effectiveness for these patients. Some background Chemoimmunotherapy remains the standard first-line treatment...
Read MoreEvaluating rituximab plus lenalidomide for first-line treatment of follicular lymphoma
In a nutshell This study evaluated the effectiveness of rituximab (Rituxan) alone or with lenalidomide (Revlimid) for the first-line treatment of follicular lymphoma (FL). This study concluded that rituximab plus lenalidomide was effective and well-tolerated in these patients. Some background Immunochemotherapy is the current standard...
Read MoreEvaluating high-dose etoposide before stem cell transplantation for patients with unresponsive diffuse large B cell lymphoma
In a nutshell This study evaluated the outcomes of patients with unresponsive diffuse B-cell lymphoma (DLBCL) after treatment with high-dose etoposide (Etopophos) and a stem cell transplant (SCT). This study concluded that this regimen was effective for some of these patients, namely those who responded to etoposide treatment. Some background DLBCL is...
Read More
